MY113757A - Methods of inhibiting endometrial cancer - Google Patents

Methods of inhibiting endometrial cancer

Info

Publication number
MY113757A
MY113757A MYPI95002449A MYPI19952449A MY113757A MY 113757 A MY113757 A MY 113757A MY PI95002449 A MYPI95002449 A MY PI95002449A MY PI19952449 A MYPI19952449 A MY PI19952449A MY 113757 A MY113757 A MY 113757A
Authority
MY
Malaysia
Prior art keywords
endometrial cancer
methods
inhibiting endometrial
inhibiting
hexamethyleneamino
Prior art date
Application number
MYPI95002449A
Other languages
English (en)
Inventor
Margaret Boss Susan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY113757A publication Critical patent/MY113757A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MYPI95002449A 1994-08-22 1995-08-21 Methods of inhibiting endometrial cancer MY113757A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29385394A 1994-08-22 1994-08-22

Publications (1)

Publication Number Publication Date
MY113757A true MY113757A (en) 2002-05-31

Family

ID=23130867

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI95002449A MY113757A (en) 1994-08-22 1995-08-21 Methods of inhibiting endometrial cancer

Country Status (17)

Country Link
EP (1) EP0777476A4 (fr)
JP (1) JPH10504824A (fr)
KR (1) KR970705387A (fr)
AU (1) AU688112B2 (fr)
CA (1) CA2198119A1 (fr)
CZ (1) CZ51897A3 (fr)
FI (1) FI970717A (fr)
HU (1) HUT76890A (fr)
IL (1) IL115022A (fr)
MX (1) MX9701327A (fr)
MY (1) MY113757A (fr)
NO (1) NO970783L (fr)
NZ (1) NZ292017A (fr)
RU (1) RU2161964C2 (fr)
TW (1) TW404834B (fr)
WO (1) WO1996005833A1 (fr)
ZA (1) ZA956994B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
CN115825414B (zh) * 2023-01-09 2023-04-25 中国医学科学院北京协和医院 血液或尿液代谢标志物及其在子宫内膜癌早筛中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
JPH08512197A (ja) * 1993-04-07 1996-12-24 リガンド・ファーマシューティカルズ・インコーポレーテッド 受容体アゴニストのスクリーニング方法
IL111287A0 (en) * 1993-10-15 1994-12-29 Lilly Co Eli Methods for treating resistant neoplasms
WO1996005832A1 (fr) * 1994-08-22 1996-02-29 Eli Lilly And Company Procedes enrayant l'hyperplasie endometriale primaire
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses

Also Published As

Publication number Publication date
AU688112B2 (en) 1998-03-05
IL115022A (en) 2000-07-31
FI970717A0 (fi) 1997-02-20
AU3370095A (en) 1996-03-14
NO970783D0 (no) 1997-02-20
CA2198119A1 (fr) 1996-02-29
TW404834B (en) 2000-09-11
JPH10504824A (ja) 1998-05-12
ZA956994B (en) 1997-02-21
WO1996005833A1 (fr) 1996-02-29
NO970783L (no) 1997-02-20
EP0777476A1 (fr) 1997-06-11
KR970705387A (ko) 1997-10-09
HUT76890A (en) 1997-12-29
EP0777476A4 (fr) 1999-06-23
FI970717A (fi) 1997-02-20
RU2161964C2 (ru) 2001-01-20
MX9701327A (es) 1997-05-31
NZ292017A (en) 2000-07-28
CZ51897A3 (en) 1997-06-11
IL115022A0 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
MY132251A (en) Methods of inhibiting cell-cell adhesion
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
MY132085A (en) Methods for inhibiting bone prosthesis degeneration
MX9709466A (es) Medicamento para inhibir el melanoma.
MY113757A (en) Methods of inhibiting endometrial cancer
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701333A (es) Metodos para inhibir el daño neuronal.
PH31620A (en) Benzothiophenes for bone healing and fracture repair.
MY131931A (en) Methods of inhibiting primary endometrial hyperplasia
MX9706520A (es) Metodos para inhibir el cancer de ovario.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9806036A (es) Compuestos para inhibir tumores en el colon.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.